GlassScriptPhysician profile
Eyad Karzoun
NPI 1649470196
$2,636.70
in general payments reported to CMS, 2019-2025
19 companies · $48.03 in 2025
The $48.03 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.67 · 2021: $57.72 · 2022: $632 · 2023: $943 · 2024: $883 · 2025: $48.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $488.91 | 2022-2024 | Smartvest |
| Glaxosmithkline, LLC. | $390.50 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $310.73 | 2022-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.84 | 2019-2024 | Ofev, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $207.37 | 2022-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $202.71 | 2021-2024 | Airsupra, Fasenra |
| Mylan Specialty L.P. | $169.13 | 2019-2024 | Yupelri |
| Genzyme Corporation | $87.13 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $80.81 | 2021-2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $75.32 | 2023-2024 | Opsumit |
| Baxter Healthcare | $74.70 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $63.87 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $54.61 | 2022-2024 | Glassia, Hyqvia |
| Amgen INC. | $50.95 | 2022 | |
| Merck Sharp & Dohme LLC | $49.41 | 2024 | Zerbaxa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.05 | 2024 | Illumisite |
| Mallinckrodt Hospital Products INC. | $19.94 | 2024 | Acthar |
| Pulmonx Corporation | $15.37 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Viatris Specialty LLC | $15.35 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eyad Karzoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.